Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

65.5K
Overview
65.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Vaccines01:30

Cancer Vaccines

251
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
251
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.

Cancer discovery·2026
Same author

Fluorine-19 MRI signal phenotype in solid tumor following in situ perfluorocarbon cell labeling.

Scientific reports·2026
Same author

Inducible, split base editors for in vivo cancer functional genomics.

Nature biotechnology·2026
Same author

Inhibitory receptor agonists: Emerging strategies in immune modulation.

The Journal of experimental medicine·2026
Same author

Intratumoral lymphatics: When less is more.

Cancer cell·2026
Same author

Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: May 12, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

221

One Step Ahead: Preventing Tumor Adaptation to Immune Therapy.

Erica L Braverman1,2, Giuliana P Mognol3, Andy J Minn4,5

  • 1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 7, 2025
PubMed
Summary

Immune checkpoint inhibitors offer cancer treatment benefits but face resistance and side effects. New therapies targeting alternate checkpoints like LAG-3 and interferon signaling show promise for improved antitumor immunity.

More Related Videos

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.4K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

502

Related Experiment Videos

Last Updated: May 12, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

221
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

7.4K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

502

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, improving survival in several cancer types.
  • However, many patients do not respond to ICIs, and acquired resistance or severe adverse events limit their efficacy.
  • Mechanisms of resistance involve T-cell exhaustion, upregulation of alternate checkpoints (e.g., LAG-3), persistent interferon signaling, and immunosuppressive myeloid cells within the tumor microenvironment (TME).

Purpose of the Study:

  • To review the mechanisms of resistance to immune checkpoint inhibitors in solid tumors.
  • To highlight emerging therapeutic strategies targeting alternate immune checkpoints and pathways involved in immune suppression.
  • To discuss recent clinical developments and approvals for novel cancer immunotherapies.

Main Methods:

  • Literature review of studies on immune checkpoint inhibitors and cancer resistance mechanisms.
  • Analysis of clinical trial data for novel immunotherapies targeting alternate checkpoints and immunosuppressive pathways.
  • Examination of the role of T-cell exhaustion, LAG-3, interferon signaling, and myeloid cells in the TME.

Main Results:

  • Chronic immune stimulation can lead to T-cell exhaustion and upregulation of alternative checkpoints like LAG-3.
  • Persistent interferon signaling in the TME can induce epigenetic changes in cancer cells, promoting immune evasion.
  • Immune-suppressive macrophages contribute to tumor progression by hindering effective anti-tumor immune responses.
  • New therapies targeting LAG-3, phosphoinositide 3-kinase gamma, and JAK inhibitors show clinical promise.

Conclusions:

  • Understanding resistance mechanisms is crucial for advancing cancer immunotherapy.
  • Targeting alternate immune checkpoints and immunosuppressive pathways offers new avenues for cancer treatment.
  • Emerging therapies demonstrate potential to overcome resistance and improve outcomes for a broader range of cancer patients.